Sign in
Taking people in PolandPhase 3

Tests budesonide in children with a kidney disease called IgA nephropathy

Tests prolonged-release budesonide with standard care in children with IgA nephropathy.

Key facts

Who runs it
Medical University Of Warsaw
Where
Bialystok, Cracow, Gdansk, Lublin, Poznan, Torun, Warsaw, and Wroclaw, PolandSee the 8 sites
Registry title
Evaluation of the efficacy and safety of prolonged-release budesonide in children with primary IgA nephropathy.
Status
Recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
7 Oct 2025
Expected to end
31 Mar 2028
Type of study
Interventional
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 8-17 years with primary IgA nephropathy confirmed by kidney biopsy and protein in the urine. It compares budesonide DR with placebo and with prednisone.

Age
8 to 17 years
Sex
Boys and girls can both join.
Disease stage
Primary IgA nephropathy diagnosed on kidney biopsy, with proteinuria >200 mg/day or protein-creatinine ratio (UPR) >0.2 g/g in three tests.
Earlier treatment
No treatment, or treatment with ACEI/ARB. Any steroid or immunosuppressive treatment must have ended at least 2 months earlier.
Biomarker or test result
Proteinuria >200 mg/day or protein-creatinine ratio (UPR) >0.2 g/g in three tests. A negative pregnancy test is needed at the start of treatment.

Main reasons for not taking part

  • Secondary forms of IgA nephropathy, such as IgA vasculitis or Crohn's disease
  • Pregnancy or breastfeeding
  • Rapidly progressive glomerulonephritis in the course of IgAN
  • GFR < 60 ml/min according to Schwartz at randomization
  • Steroid or immunosuppressive treatment now or less than 2 months before screening

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • obtaining consent from the parent/legal guardian and the patient to participate in the study
  • age 8-17 years
  • primary IgA nephropathy diagnosed on kidney biopsy
  • no treatment or treatment with ACEI/ARB
  • steroid treatment or immunosuppressive treatment completed at least 2 months previously
  • proteinuria >200 mg/day or protein-creatinine ratio (UPR) >0.2 g/g in three tests
  • negative pregnancy test result (urine platelet) at the time of qualification to start treatment

Who cannot take part

  • currently or less than 2 months before the screenig used systemic steroid therapy or immunosuppressive treatment such as: azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, cyclosporine A
  • secondary forms of IgA nephropathy, e.g. nephropathy associated with IgA vasculitis (IgAVN), IgA nephropathy in the course of Crohn's disease
  • chronic diseases that, in the opinion of the researcher, may affect the course of treatment, e.g. tuberculosis
  • severe heart disease
  • active peptic ulcer disease of the stomach and/or duodenum
  • history of prednisone intolerance
  • GFR < 60 ml/min according to Schwartz at the time of randomization
  • pregnancy or breastfeeding
  • rapidly progressive glomerulonephritis in the course of IgAN
  • cataract, glaucoma

Where in Poland

  • Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W BialymstokuBialystok, PolandTaking people
  • Uniwersytecki Szpital Dzieciecy W KrakowieCracow, PolandTaking people
  • Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Uniwersytecki Szpital Dziecięcy w LublinieLublin, PolandTaking people
  • Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego W PoznaniuPoznan, PolandTaking people
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w ToruniuTorun, PolandTaking people
  • Medical University of WarsawWarsaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

About the trial

What the trial wants to find out

1. Proving that Budesonide DR in combination with ACEI is more effective than placebo in reducing proteinuria. 2. To assess whether treatment with Budesonide DR is better than treatment with Prednisone in reducing proteinuria in the study population.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.
Plain-language title
Tests budesonide in children with a kidney disease called IgA nephropathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 March 2026